Ajanta Pharma Q4 Results FY26: PAT Rs 267 Crore Up 18 Percent, FY26 Annual PAT Rs 1056 Crore

Ajanta Pharma Q4 results FY26 reported consolidated net profit of Rs 266.70 crore for the quarter ended March 31, 2026, up 18.4 percent year on year. The Ajanta Pharma Q4 results revenue from operations stood at Rs 1,421.64 crore, driven by strong branded generics performance in India, Africa, and Asia markets. The Ajanta Pharma Q4 results capped a fiscal year where the company’s scale, geographic diversification, and branded portfolio strategy delivered consistent earnings growth.

The Ajanta Pharma Q4 results full-year FY26 PAT was Rs 1,056 crore, a significant milestone for the mid-cap pharma company. Ajanta Pharma Q4 results management highlighted continued momentum in the chronic therapy segment including cardiac, diabetology, and ophthalmology, which form the core of the company’s India branded business. Africa exports also contributed strongly to Ajanta Pharma Q4 results revenue, with the region showing resilience despite logistical challenges arising from the Iran-UAE conflict in the Gulf transit corridor.

Get Free Stock Recommendations on Univest

Ajanta Pharma Q4 FY26 Results at a Glance

Track live Ajanta Pharma financials, analyst ratings and peer comparisons on the Univest Screener.

Key Highlights from Ajanta Pharma Q4 results

18 Percent PAT Growth Reflects Quality Branded Mix in Ajanta Pharma Q4 Results

Ajanta Pharma Q4 results PAT of Rs 266.70 crore, up 18.4 percent, was driven by branded generics operating leverage in India and high-margin therapeutic areas. Chronic therapies including cardiac and diabetology command superior margins versus acute therapies. The Ajanta Pharma Q4 results EBITDA margins remained above 25 percent, reflecting pricing power in the branded segment. R&D spend as a percentage of revenue remained steady at approximately 6 to 7 percent, protecting the innovation pipeline that underpins Ajanta Pharma Q4 results long-term competitiveness.

FY26 PAT Crossing Rs 1056 Crore is Milestone in Ajanta Pharma Q4 Results Commentary

Ajanta Pharma Q4 results management confirmed full-year FY26 PAT of Rs 1,056 crore, crossing the Rs 1,000 crore threshold for the first time. This milestone reflects the successful execution of the company’s branded generics strategy across India, Africa, and South-East Asia markets embedded in Ajanta Pharma Q4 results. The FY26 performance provides a strong base for FY27 earnings growth as new product launches in the ophthalmology and dermatology segments are planned.

What Drove Ajanta Pharma Q4 FY26 Performance

Ajanta Pharma Q4 results performance was driven by strong India branded generic volumes in chronic segments, Africa institutional business resilience, and contained input cost inflation. The ophthalmic and cardiac therapy franchises delivered above-market growth in Ajanta Pharma Q4 results. Operating leverage from fixed manufacturing costs at Palghar and Dahej facilities improved EBITDA margins. The company’s differentiated branded strategy in emerging markets gives Ajanta Pharma Q4 results a premium earnings quality versus generic-focused peers.

Outlook for FY27

Following Ajanta Pharma Q4 results, FY27 outlook is positive with new chronic therapy launches in India, Africa institutional contract wins, and potential US generics business contribution from FDA-cleared products. Management at Ajanta Pharma Q4 results briefing highlighted R&D pipeline progress in complex generics and biosimilars that could provide incremental revenue beyond FY27. Analyst targets for Ajanta Pharma post Q4 results range between Rs 2,800 and Rs 3,400.

Conclusion

Ajanta Pharma Q4 results FY26 confirm 18.4 percent PAT growth to Rs 266.70 crore and FY26 full-year PAT of Rs 1,056 crore, a historic milestone. Revenue of Rs 1,421.64 crore on strong branded generics performance in India and Africa positions Ajanta Pharma Q4 results as a quality mid-cap pharma compounder. Track Ajanta Pharma Q4 results live data on the Univest Screener.

Download the Univest iOS App or Univest Android App for live Ajanta Pharma Q4 results tracking and expert research.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making investment decisions.

Frequently Asked Questions

What was the Ajanta Pharma Q4 results FY26 net profit?

Ajanta Pharma Q4 results FY26 reported consolidated PAT of Rs 266.70 crore, up 18.4 percent year on year. FY26 full-year PAT crossed Rs 1,056 crore, the first time above Rs 1,000 crore in company history.

What was the Ajanta Pharma Q4 results FY26 revenue?

Ajanta Pharma Q4 results FY26 revenue from operations was Rs 1,421.64 crore, driven by branded generics in India chronic therapy segments and Africa institutional business exports.

What are the key strengths in Ajanta Pharma Q4 results FY26?

Key strengths in Ajanta Pharma Q4 results include branded generics pricing power in India, Africa market diversification, EBITDA margins above 25 percent, and a growing chronic therapy franchise in cardiac, diabetology, and ophthalmology.

What is the outlook after Ajanta Pharma Q4 results FY26?

Following Ajanta Pharma Q4 results, FY27 outlook is positive with new chronic launches, Africa contract wins, and US generics pipeline. Analyst targets range Rs 2,800 to Rs 3,400 for Ajanta Pharma post Q4 results.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026